Argenx Sales Rise 54% to $1.7 Billion in Third Quarter
Key Facts
Argenx reported global net sales of Vyvgart products of about $1.7 billion in its third-quarter 2026 results, released on October 22, as sales continued to grow from a year earlier and the previous quarter. The company said in its statement that sales recorded "growth of 54% year on year and 13% compared with the previous quarter," extending gains from the prior period. Product sales had reached about $1.5 billion in the second quarter of 2026, according to the company's disclosure for that period. The company reported annual growth of 60% at the time, a faster pace than the annual growth it announced for the third quarter. The latest sales results thus combined an increase in value from the previous quarter with slower growth compared with the same period a year earlier.
Argenx posted net profit of $506 million in the third quarter of 2026, according to the results published by the company. Diluted earnings per share were $7.80 for the period, compared with $5.18 in the third quarter of 2025, putting earnings per share above the year-earlier level. At the end of September, cash, cash equivalents and current financial assets totaled $3.7 billion, according to the earnings statement. In the stock market, the company's shares, traded under the ticker ARGX, closed at $890.05 on October 21, 2026, according to EL7 data. That close came in the session before the quarterly results announcement, which coincided with the scheduled date of the company's call to discuss them the following day.
Third-quarter selling, general and administrative expenses included about $150 million in expenses associated with the acquisition of Forte Biosciences, according to Argenx. For the full year 2026, the company expects combined research and development and selling, general and administrative expenses of approximately $4 billion, including costs related to the Forte deal. In its October update on its celiac disease treatment, Argenx said it planned to advance the experimental therapy FB102 into Phase 3 clinical development. The treatment's study met its primary endpoint measuring the change from baseline in the ratio of intestinal villous height to crypt depth, according to the study statement. The company reported a p-value of 0.0176 for that endpoint as part of the results it announced alongside its plan to move the treatment into the next stage of development.
In its immune-mediated myositis program, Argenx announced that the ALKIVIA study showed the treatment outperformed placebo by 15.4 points in the mean Total Improvement Score. The difference reflects a comparison of improvement between the treatment and placebo on the scale used in the study, according to the company's statement on the ALKIVIA data. In a separate Sjogren's treatment program, the company decided to discontinue the UNITY study following an independent monitoring committee's assessment of its ability to meet its primary endpoint. Argenx said the committee concluded that "the UNITY study is unable to meet its primary endpoint," a finding that formed the basis for the decision to discontinue it. The company added in the same disclosure that "no new safety signals were observed," while the committee's conclusion concerned the study's inability to meet its primary endpoint.
Argenx scheduled its third-quarter earnings call for October 22, 2026, at 8:30 a.m. U.S. Eastern Time, according to its announcement of the call. On upcoming clinical disclosures, the company plans to present data from the ALKIVIA study in immune-mediated myositis on November 11, 2026. It scheduled the presentation for 9:15 to 9:30 a.m. U.S. Eastern Time, according to its announcement on the study data presentation. The date is part of the company's clinical data presentation schedule, ahead of its next annual financial disclosure. Argenx set February 25, 2027, as the date for announcing its fiscal 2026 results and fourth-quarter business update, according to the schedule published with its second-quarter results.